Literature DB >> 16271063

Diagnosis and management of staphylococcal infections of vascular grafts and stents.

S T Chambers1.   

Abstract

Staphylococcus aureus and coagulase-negative staphylococci are the commonest bacterial causes of both vascular graft and stent infections. Infection may occur either from direct implantation or haematogenous spread, and occurs in less than 1% of aortic grafts, 2% to 5% of inguinal grafts, and rarely in stents. Death or amputation is common following these infections despite aggressive treatment. Infection with S. aureus is usually more acute than with coagulase-negative staphylococci but both cause systemic symptoms. Inguinal infections usually cause localized swelling often with a sinus tract, bleeding or distal embolism. Aortic infections commonly present with abdominal discomfort retroperitoneal infection or a mass from a false aneurysm. Stent infections usually cause pain, swelling, erythema and circulation disturbances of the ipsilateral limb. The most useful investigations are blood cultures and computerized tomography or magnetic resonance imaging. These imaging techniques have a high sensitivity and specificity in advanced graft infections but these are considerably lower in low-grade infections. Persistence of perigraft fluid beyond 3 months after surgery is suspicious of infection. Aggressive antimicrobial therapy is an important part of management but surgery is usually required to cure both graft and stent infections. Where the organisms are susceptible, high-dose beta-lactam therapy (e.g. flucloxacillin, dicloxacillin or a first-generation cephalosporin) plus low-dose gentamicin are recommended initially. Some authorities add rifampicin after 3-5 days treatment, but this is controversial. Antimicrobial therapy can be stopped 4-6 weeks after surgery if arterial stump cultures are negative but should be continued long-term, and perhaps indefinitely, if they are positive.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16271063     DOI: 10.1111/j.1444-0903.2005.00981.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  8 in total

1.  Bacterial translocation across ePTFE vascular graft surfaces.

Authors:  Supriya Narasimhan; Saima Aslam; Peter H Lin; Carlos F Bechara; Mohammad D Mansouri; Rabih O Darouiche
Journal:  J Infect       Date:  2010-04-01       Impact factor: 6.072

2.  Endovascular infection following inferior vena cava (IVC) filter insertion.

Authors:  Amihai Rottenstreich; Rachel Bar-Shalom; Allan I Bloom; Yosef Kalish
Journal:  J Thromb Thrombolysis       Date:  2015-11       Impact factor: 2.300

3.  Splenic artery switch for revascularization of the liver: a salvage procedure for inflammatory arterial hemorrhage.

Authors:  F Kröpil; M Schauer; M Krausch; P Kröpil; S A Topp; A M Raffel; C F Eisenberger; Wolfram T Knoefel
Journal:  World J Surg       Date:  2013-03       Impact factor: 3.352

Review 4.  Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications.

Authors:  Benjamin P Howden; John K Davies; Paul D R Johnson; Timothy P Stinear; M Lindsay Grayson
Journal:  Clin Microbiol Rev       Date:  2010-01       Impact factor: 26.132

Review 5.  Cross-sectional imaging of aortic infections.

Authors:  D J Murphy; A R Keraliya; M D Agrawal; A Aghayev; M L Steigner
Journal:  Insights Imaging       Date:  2016-10-19

6.  Systemic thioridazine in combination with dicloxacillin against early aortic graft infections caused by Staphylococcus aureus in a porcine model: In vivo results do not reproduce the in vitro synergistic activity.

Authors:  Michael Stenger; Carsten Behr-Rasmussen; Kasper Klein; Rasmus B Grønnemose; Thomas Emil Andersen; Janne K Klitgaard; Hans Jørn Kolmos; Jes S Lindholt
Journal:  PLoS One       Date:  2017-03-09       Impact factor: 3.240

7.  Case report: Vascular graft infection due to Aspergillus species presenting with recurrent vascular occlusion.

Authors:  Ayami Tano; Koichi Kato; Yoshimasa Seike; Hitoshi Matsuda; Takashi Suzue; Yoshihiro Kaneko; Misato Kodama; Yuichi Sawayama; Akashi Miyamoto; Noriaki Yagi; Yoshihisa Nakagawa
Journal:  BMC Cardiovasc Disord       Date:  2022-04-01       Impact factor: 2.298

Review 8.  Development of a multicomponent Staphylococcus aureus vaccine designed to counter multiple bacterial virulence factors.

Authors:  Annaliesa S Anderson; Alita A Miller; Robert G K Donald; Ingrid L Scully; Jasdeep S Nanra; David Cooper; Kathrin U Jansen
Journal:  Hum Vaccin Immunother       Date:  2012-08-24       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.